Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy
Abstract Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug deliver...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Bioengineering & Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/btm2.10482 |
| _version_ | 1797556855205003264 |
|---|---|
| author | Jianzhong Zhang Xue Liu Yutian Xia Shuyu Xu Xuan Liu Haiqing Xiao Xiaoyong Wang Chao Liu Gang Liu |
| author_facet | Jianzhong Zhang Xue Liu Yutian Xia Shuyu Xu Xuan Liu Haiqing Xiao Xiaoyong Wang Chao Liu Gang Liu |
| author_sort | Jianzhong Zhang |
| collection | DOAJ |
| description | Abstract Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platform was proposed and validated for targeted cancer combination therapy. VAM generated from the cellular plasma membrane was bio‐synthetically fabricated, with the recombinant protein (hGC33 scFv‐melittin) being harbored and displayed on the cell membrane. The bioactive and targetable nanomelittin conjugated by hGC33 scFv could be released in an MMP14‐responsive manner at tumor sites, which reduced off‐target toxicity, especially the hemolytic activity of melittin. Importantly, VAM could be loaded with small‐molecule drugs or nanoparticles for combination therapy. Nanomelittin formed pores in membranes and disturbed phospholipid bilayers, which allowed the anticancer agents (i.e., chemotherapeutic drug doxorubicin and sonosensitizer purpurin 18 nanoparticles) co‐delivered by VAM to penetrate deeper tumor sites, leading to synergistic therapeutic effects. In particular, the punching effect generated by sonodynamic therapy further improved the immunomodulatory effect of nanomelittin to activate the immune response. Taken together, our findings indicate that clinically translatable VAM‐based strategies represent a universal, promising approach to multimodal synergetic cancer therapy. |
| first_indexed | 2024-03-10T17:08:51Z |
| format | Article |
| id | doaj.art-7c9c8a4fea8248c49011587f866105d9 |
| institution | Directory Open Access Journal |
| issn | 2380-6761 |
| language | English |
| last_indexed | 2024-03-10T17:08:51Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Bioengineering & Translational Medicine |
| spelling | doaj.art-7c9c8a4fea8248c49011587f866105d92023-11-20T10:44:13ZengWileyBioengineering & Translational Medicine2380-67612023-11-0186n/an/a10.1002/btm2.10482Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapyJianzhong Zhang0Xue Liu1Yutian Xia2Shuyu Xu3Xuan Liu4Haiqing Xiao5Xiaoyong Wang6Chao Liu7Gang Liu8State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen ChinaAbstract Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platform was proposed and validated for targeted cancer combination therapy. VAM generated from the cellular plasma membrane was bio‐synthetically fabricated, with the recombinant protein (hGC33 scFv‐melittin) being harbored and displayed on the cell membrane. The bioactive and targetable nanomelittin conjugated by hGC33 scFv could be released in an MMP14‐responsive manner at tumor sites, which reduced off‐target toxicity, especially the hemolytic activity of melittin. Importantly, VAM could be loaded with small‐molecule drugs or nanoparticles for combination therapy. Nanomelittin formed pores in membranes and disturbed phospholipid bilayers, which allowed the anticancer agents (i.e., chemotherapeutic drug doxorubicin and sonosensitizer purpurin 18 nanoparticles) co‐delivered by VAM to penetrate deeper tumor sites, leading to synergistic therapeutic effects. In particular, the punching effect generated by sonodynamic therapy further improved the immunomodulatory effect of nanomelittin to activate the immune response. Taken together, our findings indicate that clinically translatable VAM‐based strategies represent a universal, promising approach to multimodal synergetic cancer therapy.https://doi.org/10.1002/btm2.10482Cancer therapyDrug deliveryMelittinMembrane vesiclesNanomedicine |
| spellingShingle | Jianzhong Zhang Xue Liu Yutian Xia Shuyu Xu Xuan Liu Haiqing Xiao Xiaoyong Wang Chao Liu Gang Liu Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy Bioengineering & Translational Medicine Cancer therapy Drug delivery Melittin Membrane vesicles Nanomedicine |
| title | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
| title_full | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
| title_fullStr | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
| title_full_unstemmed | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
| title_short | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
| title_sort | genetically engineered nano melittin vesicles for multimodal synergetic cancer therapy |
| topic | Cancer therapy Drug delivery Melittin Membrane vesicles Nanomedicine |
| url | https://doi.org/10.1002/btm2.10482 |
| work_keys_str_mv | AT jianzhongzhang geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT xueliu geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT yutianxia geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT shuyuxu geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT xuanliu geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT haiqingxiao geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT xiaoyongwang geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT chaoliu geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT gangliu geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy |